[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ray Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100626765","phase-1-phase-12-open-label-dose-escalation-study-to-evaluate-safety-of-a-single-intravitreal-injection-of-rtx-021-in-patients-with-stargardt-disease-100626765",false,"NCT07439887","Phase 1\u002F2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease","Phase 1\u002F2, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease (AURORA)","AURORA","Inclusion Criteria:\n\n* Male and female patients \\>= 16 years of age\n* Able to comply with the study visit schedule and all protocol assessments\n* Diagnosis of Stargardt Disease (genetic testing required)\n* Study eye and fellow eye Best Corrected Visual Acuity meeting study criteria\n* Presence of retinal ganglion cells and\u002For retinal nerve fiber layer on Spectral Domain Optical Coherence Tomography testing at Screening confirmed by central image reading center\n* Adequate organ function and general good health\n\nExclusion Criteria:\n\n* Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent, or therapy in the past six months\n* Concurrent participation in another interventional clinical ocular study\n* Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy\n* Pre-existing eye conditions in either eye that would preclude the planned treatment or are significant enough to interfere with the interpretation of study endpoints or procedural complications\n* Known steroid responders if their intraocular pressure was not able to be managed effectively with topical pressure-lowering medications after prior use of steroid medications\n* Complicating systemic diseases including those in which the disease itself, or the treatment of the disease, can alter ocular and\u002For central nervous system function (e.g. radiation treatment of the orbit; leukemia with optic nerve involvement)\n* Any immunological response dysfunction including, immuno-compromising diseases or use of immunosuppressive medications, among others\n* Cataract or other ocular (including refractive) surgery, intraocular and\u002For peri-ocular injection in either eye within the prior four months (i.e. 120 days) prior to screening\n* Prior vitrectomy or aphakia in the study eye\n* Known sensitivity to any component of the study treatment or contraindication to medications planned for use in the peri-procedural period (e.g. povidone-iodine to prep for intravitreal injection)\n* Known contraindication to prophylactic steroid regimen\n* Current pregnancy or breastfeeding\n* Any other condition that would not allow the patient to complete follow-up examinations during the study","ALL","16 Years",{"count":20,"type":21},18,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","A Phase 1\u002F2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years.",[28],"Stargardt Disease",[15,30],"RTx-021","RECRUITING","2026-04-13",{"date":34,"type":35},"2026-04-15","ACTUAL",{"date":37,"type":35},"2026-01-28",{"date":39,"type":21},"2030-12-01",{"name":41,"class":42},"Ray Therapeutics, Inc.","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100631590","development-and-evaluation-of-functional-visual-field-and-navigation-endpoints-in-moderate-to-profound-inherited-retinal-disease-define-ird-100631590","NCT07502664","Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)","DEFINE-IRD","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F200 to HM in at least one eye.\n* Reasonably fluent in English or Spanish\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient","18 Years",{"count":52,"type":21},25,"OBSERVATIONAL","The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.\n\nThe mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.\n\nThe VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.",[56,57,28,58,59,60],"Retinitis Pigmentosa","Stargardt Macular Dystrophy","Geographic Atrophy From Age-related Macular Degeneration","X-linked Retinoschisis","Retinal Dystrophies","2026-03-24",{"date":63,"type":35},"2026-03-31",{"date":65,"type":35},"2026-02-19",{"date":67,"type":21},"2027-02",{"name":41,"class":42},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":69},"100544926","observational-study-to-assess-endpoint-operational-feasibility--measurement-properties-in-patients-with-retinal-degeneration-100544926","NCT06375239","Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F70 and HM in at least one eye as tested with clinic-based visual acuity method\n* Reasonably fluent in English\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient",{"count":78,"type":21},120,[56,80,57,28,81,82,60],"Choroideremia","Geographic Atrophy from Age-related Macular Degeneration","X-lined Retinoschisis","2025-01-06",{"date":85,"type":35},"2025-01-08",{"date":87,"type":35},"2024-04-05",{"date":89,"type":21},"2026-04-30",{"name":41,"class":42},""]